M
M. Miller
Researcher at Novartis
Publications - 27
Citations - 537
M. Miller is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & Letrozole. The author has an hindex of 10, co-authored 27 publications receiving 269 citations.
Papers
More filters
Journal ArticleDOI
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Fabrice Andre,Eva Ciruelos,Dejan Juric,S. Loibl,M. Campone,Ingrid A. Mayer,G. Rubovszky,Toshinari Yamashita,Bella Kaufman,Yung-Feng Lu,Kenichi Inoue,Zsuzsanna Papai,Masato Takahashi,Farhat Ghaznawi,David Mills,M. Kaper,M. Miller,Pierfranco Conte,H. Iwata,Hope S. Rugo +19 more
TL;DR: Overall, these results further support the statistically significant prolongation of PFS observed with alpelisib plus fulvestrant in this population, which has a poor prognosis due to a PIK3CA mutation.
Journal ArticleDOI
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Hope S. Rugo,Fabrice Andre,Toshinari Yamashita,H. Cerda,I. Toledano,Salomon M. Stemmer,J.C. Jurado,Dejan Juric,Ingrid A. Mayer,Eva Ciruelos,H. Iwata,Pierfranco Conte,M. Campone,C. Wilke,David Mills,Agnes Lteif,M. Miller,F. Gaudenzi,S. Loibl +18 more
TL;DR: Early identification, prevention, and intervention, including concomitant medications and alpelisib dose modifications, resulted in less severe toxicities and support the need for optimal AE management.
Journal ArticleDOI
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Katarína Petráková,Kimberly L. Blackwell,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Fengjuan Xuan,M. Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +19 more
TL;DR: In this article, the authors reported updated efficacy and safety data from MONALEESA-2 with a further ~11 months of follow-up, showing that ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + letrozole (LET) significantly prolonged progression-free survival (PFS) vs placebo (PBO) + LET in patients with HR+, HER2-ABC.
Journal ArticleDOI
Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))
Gabriel N. Hortobagyi,Salomon M. Stemmer,H. A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,M. Campone,K. Petrakova,K. L. Blackwell,EP Winer,Wolfgang Janni,S. Verma,Pierfranco Conte,CL Arteaga,David Cameron,S. Mondal,Faye Su,M. Miller,Mohamed Elmeliegy,C. Germa,Joyce A. O'Shaughnessy +20 more
Journal ArticleDOI
Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.
Dennis J. Slamon,Patrick Neven,Stephen Chia,Seock-Ah Im,Peter A. Fasching,Michelino DeLaurentiis,Katarína Petráková,Giulia Bianchi,Francisco J. Esteva,Miguel Martín,Xavier Pivot,Gena Vidam,Yingbo Wang,Cristina Karen Rodriguez Lorenc,M. Miller,Tanya Taran,Guy Jerusalem +16 more
TL;DR: First-line RIB + letrozole significantly prolonged progression-free survival in postmenopausal women with HR+, HER2– ABC and MONALEESA-3 (NCT02422615) results are reported.